The DOI matches its Crossref record.
Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.
Abstract
PURPOSE: To determine the maximum-tolerated dose (MTD) of paclitaxel administered as a 3-hour infusion in patients with recurrent malignant glioma. PATIENTS AND METHODS: Patients were stratified by starting dose of paclitaxel and concurrent anticonvulsant (AC) use and were treated in cohorts of three patients. The starting dose was 240 mg/m2 administered intravenously with escalations of 30 mg/m2 until the MTD was established. Pharmacokinetic data were obtained for each patient for the first infusion. Tumor response was assessed at 6-week intervals and treatment was continued until documented tumor progression, unacceptable toxicity, or a total of 12 paclitaxel infusions. RESULTS: From April 1995 to December 1996, 34 patients were treated; 27 patients in the AC group and seven patients in the non-AC group. The MTD for patients who received ACs was established at 360 mg/m2 and the dose-limiting toxicity (DLT) was central neurotoxicity, characterized as transient encephalopathy and seizures. In contrast, the MTD for patients who did not receive ACs was 240 mg/m2, and myelosuppression, gastrointestinal toxicity, and fatigue were the DLTs. Pharmacokinetic data confirmed that the plasma drug levels and clearance rates were similar for patients in both groups at the respective dose levels that produced DLTs. CONCLUSION: The pharmacokinetics of paclitaxel are altered by ACs, and significantly larger doses of the drug can be administered to patients with brain tumors on AC therapy. The toxicity profile is different for patients on AC therapy treated at these higher doses. A phase II study has been initiated that uses a dose of 330 mg/m2 for patients on AC therapy and 210 mg/m2 for patients not on AC therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glantz, M. J., Cole, B. F., Forsyth, P. A., Recht, L. D., Wen, P. Y., Chamberlain, M. C., Grossman, S. A., & Cairncross, J. G. (2000) · Neurology · doi:10.1212/wnl.54.10.1886 · Cited by 858
Metabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 711
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Effects of St. John's wort on irinotecan metabolism.
Mathijssen, R. H. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1247 · Cited by 457
Clinical Pharmacokinetics of Docetaxel
Clarke, S. J., & Rivory, L. P. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936020-00002 · Cited by 446
Enzyme induction with antiepileptic drugs: Cause for concern?
Brodie, M. J., Mintzer, S., Pack, A. M., Gidal, B. E., Vecht, C. J., & Schmidt, D. (2013) · Epilepsia · doi:10.1111/j.1528-1167.2012.03671.x · Cited by 383
Lidar, Z., Mardor, Y., Jonas, T., Pfeffer, R., Faibel, M., Nass, D., Hadani, M., & Ram, Z. (2004) · Journal of Neurosurgery · doi:10.3171/jns.2004.100.3.0472 · Cited by 342
Mo, H., & Elson, C. E. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422900701 · Cited by 340
Kelly, W. K., & Marks, P. A. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0106 · Cited by 330
Recent Advances in the Treatment of Malignant Astrocytoma
Reardon, D. A., Rich, J. N., Friedman, H. S., & Bigner, D. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5302 · Cited by 307
Interactions between antiepileptic and chemotherapeutic drugs
Vecht, C. J., Wagner, G. L., & Wilms, E. B. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00435-6 · Cited by 256
Histone deacetylase inhibitors: from target to clinical trials
Kelly, W. K., O’Connor, O. A., & Marks, P. A. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.12.1695 · Cited by 253
Doze, F. L., Debruyne, D., Albessard, F., Barre, L., & Defer, G. L. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15129-x · Cited by 54
“124 h (Chou et al., 1997) or 0.69 h (Shelley et al., 1982) after an oral dose of 2 or 13.9 mg/kg, respectively; the AUC was 13,740 6 1600 ng.h/ml after an oral dose of 13.9 mg/kg (Shelley et al., 1982). The blood pharmacokinetic data for 13-cis RA were also consistent with the data published by Guchelaar et al. (1992)…”
Influential
Metadata
- Authors
- Chang, S. M., Kuhn, J. G., Rizzo, J., Robins, H. I., Schold, S. C., Spence, A. M., Berger, M. S., Mehta, M. P., Bozik, M. E., Pollack, I., Gilbert, M., Fulton, D., Rankin, C., Malec, M., & Prados, M. D.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-06
- Volume
- 16
- Issue
- 6
- Pages
- 2188-2194
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2080969227
- Cited by
- 166
- References
- 0
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.